T2 Biosystems

T2 Biosystems, Inc. engages in the development of a proprietary technology platform. It offers the T2 Magnetic Resonance technology, which enables detection of pathogens, biomarkers, and other abnormalities in a range of unpurified patient sample types. The firm's products include the T2Dx Instrument, the T2Candida Panel, the T2Bacteria Panel, the T2Resistance Panel, and the T2SARS-CoV-2 Panel. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

T2 Biosystems reports revenue growth, eyes FDA breakthroughs for expansion

T2 Biosystems demonstrated strong revenue growth and operational improvements in Q3 2024, driven by sepsis test panel sales and strategic partnerships.
While facing financial challenges and regulatory complexities, the company's focus on innovation and market expansion presents significant opportunities for future growth.
Overall, T2 Biosystems remains optimistic about its growth prospects, supported by advancements in its product pipeline and collaborations to combat healthcare challenges.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

T2 Biosystems, Inc. is a vitro diagnostics company, which engages in the development of detection of sepsis-causing pathogens. It offers T2Dx instrument, T2Bacteria, T2Candida, T2Biothreat panels, and T2MR technology. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

LEXINGTON, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Members of management are scheduled to host a fireside chat on Thursday, September 21, 2023, at 10:30am ET.

T2 Biosystems to Participate in the Gilmartin Group Emerging Growth Company Showcase

Shares of T2 Biosystems (NASDAQ: TTOO ) stock are currently trading below $1. However, the company's upcoming annual meeting of stockholders seeks to resolve this.

Dear TTOO Stock Fans, Mark Your Calendars for Sept. 12

Ardelyx

The RealReal

Wheels Up Experience

When it comes to stock trading, penny stocks stand out, captivating many with the promise of substantial returns. These stocks, often priced under $5 per share, belong to smaller companies and typically don't trade on the major stock exchanges.

Best Penny Stocks To Buy Now? 4 To Watch Before Labor Day

The U.S. Centers for Disease Control and Prevention Releases 2023 Hospital Sepsis Program Core Elements The U.S. Centers for Disease Control and Prevention Releases 2023 Hospital Sepsis Program Core Elements

T2 Biosystems Praises CDC's Actions Aimed at Optimizing U.S. Hospital Sepsis Programs

T2 Biosystems (NASDAQ: TTOO) stock price retreated in the past few weeks as the recent rebound lost momentum. After peaking at $0.6960 this month, the shares have pulled back by ~45% to $0.40, giving it a market cap of $117 million.

TTOO stock price has recoiled: Is it safe to buy T2 Biosystems?

Athersys

Cano Health

eFFECTOR Therapeutics Inc

Genius Group Ltd

Canoo

Pieris Pharma

Penny stocks, often priced under $1, have long been the allure for many investors seeking high-risk, high-reward opportunities. These stocks, typically from smaller companies, offer the tantalizing possibility of significant returns.

7 Best Penny Stocks To Buy Under $1 in 2023: Big Risk, Big Return?

T2 Biosystems (NASDAQ: TTOO ) stock is down by about 15% today after the healthcare diagnostics company filed a Form S-3. The filing documents the resale of up to 141.64 million shares from selling stockholders.

T2 Biosystems Preps to Resell 141 Million Shares of TTOO Stock

On Sept. 12, T2 Biosystems (NASDAQ: TTOO ) will hold its annual meeting of stockholders. Up for vote are a total of nine proposals, which include a reverse stock split in a range between 1-for-50 and 1-for-150.

TTOO Stock Alert: T2 Biosystems Seeks Approval for Reverse Stock Split

T2 Biosystems Inc. is offering “highly differentiated” products in the fight against sepsis, according to CEO John Sperzel.

T2 Biosystems touts ‘highly differentiated' products in fight against sepsis

Volatility has been the name of the game for T2 Biosciences this week. Shares of the company are down more than 8% after hours Friday to $0.56 — after gaining nearly 24% during the Friday session.

T2 Biosystems shares retreat in extended trading after another massive session Friday

T2 Biosystems (NASDAQ:TTOO) shares fell 15% at the open on Thursday after snapping its three-day winning streak the day before, down 3.8% at $0.57 at Wednesday's close. The company, which develops in vitro diagnostics tools for laboratories and hospitals, has seen its stock rally as much as more than 500% in August on meme-like buzz.

T2 Biosystems shares slide after snapping winning streak

Shares of micro cap T2 Biosystems Inc. TTOO, -3.77% plunged 12.2% in premarket trades Thursday. The health diagnostics company's stock ended Wednesday's session down 3.8%, snapping a three-day winning streak.

T2 Biosystems stock falls 12.3% premarket after snapping 3-day winning streak

The small-cap penny stock market has been hot lately, with a surge in volume and activity across several names. The most in-play name, with price and volume soaring remarkably, has been T2 Biosystems NASDAQ: TTOO.

TTOO's 375% Surge In A Month: Unveiling the Driving Forces

T2 Biosystems (NASDAQ:TTOO) shares have added about 400% in the last month as it became Wall Street's latest struggling stock to gain meme status. But what is it and why has it captured the attention of meme stock traders?

T2 Biosystems: what is it and why is it up 400% in August?

Shares of micro cap T2 Biosystems Inc. TTOO rose 4.1% in premarket trades Wednesday, continuing their rally. The health diagnostics company's stock ended Monday's session up 51.6% for their highest one-day percentage gain since Aug. 2, when the shares rose 54.3%.The stock is on a three-day winning streak.

T2 Biosystems stock climbs more than 4% premarket to continue rally

Shares of T2 Biosystems (NASDAQ:TTOO) rose more than 35% on Tuesday, continuing the stock's two-day winning streak as the stock benefits from “meme-like” buzz.  T2 Biosystems (NASDAQ:TTOO) has gained about 385% in the last month.

T2 Biosystems shares fly after sparking meme-like buzz

Shares of micro cap T2 Biosystems Inc. TTOO rose 14.3% in premarket trades Tuesday, continuing a rally that saw the stock end Monday's session up 15.4%. The stock is on a two-day winning streak after ending Friday's session up 3.3%.

T2 Biosystems stock surges more than 14% premarket to continue rally

T2 Biosystems (NASDAQ: TTOO) stock has woken up recently even as concerns about the company remain. The shares soared to a high of $0.4453 last week, the highest level since April.

TTOO stock price is pumping: Is T2 Biosystems a good buy?

Lucid Group

Snap

This article is an excerpt from the InvestorPlace Digest newsletter. To get news like this delivered straight to your inbox, click here.

4 Meme Stocks to Sell Before They Die

T2 Biosystems (NASDAQ:TTOO) shares have risen almost 200% so far this month on meme stock interest, trading hands at about US$0.31 on Friday morning. Before the highly shorted healthcare stock caught the eye of meme-stock traders, it had traded at about US$0.15.

T2 Biosystems shares surge on meme stock interest amid Nasdaq compliance challenges

T2 Biosystems Inc.'s stock TTOO, -4.50% fell 4.1% in premarket trades Friday as the developer of in vitro diagnostics products continued its pullback after ending Thursday's session down 4.5% to snap a two-day winning streak. The stock fell on trading volume of 137.31 million shares, well above its 65-day average trading volume of 83.68 million shares.

T2 Biosystems stock falls 4.1% premarket

Shares of Massachusetts-based T2 Biosystems (NASDAQ: TTOO ) surged another 30% this week on meme stock interest. According to financial data provider Fintel.io, retail ownership has now risen over six-fold since last month.

T2 Biosystems (TTOO) Stock Is Becoming the Next Mullen

AMC Entertainment

Tilray Brands

Meme stocks are exciting, and they often seem like a way to make a ton of money in a short amount of time.  The rise of Wall Street Bets and the retail trading movement in 2021 changed America's financial markets.

3 Meme Stocks to Sell in August Before They Crash and Burn

Rite Aid

Earlier this week, InvestorPlace's Thomas Yeung posed an interesting question: Could Rite Aid (NYSE: RAD ) become the next big meme stock? As meme stocks surged last week, The Wall Street Journal flagged the struggling pharmaceutical chain as a likely contender for the next r/WallStreetBets favorite.

TTOO vs. RAD Stock: Which New Meme Stock Is the Worst Buy?

It seems like T2 Biosystems (NASDAQ: TTOO ) stock will live to see another day after regaining compliance with Nasdaq's minimum market value of listed securities policy. Indeed, this morning, T2 published a note confirming that Nasdaq has given the company written notice that the market value of its listed securities is now acceptable.

News for T2 Biosystems Stock (TTOO)